Elevated serum interleukin-18 levels might reflect the high risk of hospitalization in patients on peritoneal dialysis

Nephrology

Volumn 10, Issue 6, 2005, Pages 576-582

  Yano, A I ^a   Nakao, Kazushi ^a   Sarai, A I ^a   Akagi, Shigeru ^a   Kihara, Takashi ^a   Morimoto, Hisanori ^a   Nakamura, Akihiko ^b   Hiramatsu, Makoto ^b   Nagake, Yoshio ^c   Makino, Hirofumi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA SAISEIKAI GENERAL HOSPITAL   (Japan)

^c Nagake Clinic   (Japan)

Author keywords

Asymmetric dimethylarginine; Hospitalization; Interleukin 18; Peritoneal dialysis

Indexed keywords

BETA 2 MICROGLOBULIN; INTERLEUKIN 18; N(G),N(G) DIMETHYLARGININE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; MALE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; RISK FACTOR;

AGED; ARGININE; ATHEROSCLEROSIS; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; FEMALE; HOSPITALIZATION; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-18; KIDNEY FAILURE, CHRONIC; MALE; PERITONEAL DIALYSIS; RISK FACTORS;

EID: 29144459564     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2005.00497.x     Document Type: Article

References (32)

1. Collins AJ, Kasiske B, Herzog C et al. Excerpts from the United States Renal Data System 2003 Annual Data Report: Atlas of endstage renal disease in the United States. Am. J. Kidney Dis. 2003; 42 (6 Suppl. 5): A5-7.
2. European Dialysis Transplant Association, European Renal Association. Report on management of renal failure in Europe. XXIV, 1993. Nephrol. Dial. Transplant. 1995; 10 (Suppl. 5): 1-25.
3. Rayner HC, Pisoni RL, Bommer J et al. Mortality and hospitalization in haemodialysis patients in five European countries: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol. Dial. Transplant. 2004; 19: 108-20.
4. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 1999; 340: 115-26.
5. Stenvinkel P. Inflammatory and atherosclerotic interactions in the depleted uremic patient. Blood Purif. 2001; 19: 53-61.
6. Noh H, Lee SW, Kang SW et al. Serum C-reactive protein: A predictor of mortality in continuous ambulatory peritoneal dialysis patients. Perit. Dial. Int. 1998; 18: 387-94.
7. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int. 1999; 55: 648-58.
8. Gangemi S, Mallamace A, Minciullo PL et al. Involvement of interleukin-18 in patients on maintenance haemodialysis. Am. J. Nephrol. 2002; 22: 417-21.
9. Uchimura T, Motomiya Y, Okamura H et al. Marked increases in macrophage colony-stimulating factor and interleukin-18 in maintenance hemodialysis patients: Comparative study of advanced glycation end products, carboxymethyllysine and pentosidine. Nephron 2002; 90: 401-7.
10. Mallat Z, Corbaz A, Scoazec A et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001; 104: 1598-603.
11. Descamps-Latscha B, Jungers P. New molecular aspects of chronic uraemia and dialysis-related immunocompetent cell activation. Nephrol. Dial. Transplant. 1996; 11 (Suppl. 2): 121-4.
12. Wieslander AP, Kjellstrand PT, Rippe B. Heat sterilization of glucose-containing fluids for peritoneal dialysis: Biological consequences of chemical alterations. Perit. Dial. Int. 1995; 15 (Suppl. 7): S52-S59.
13. Nakayama M, Kawaguchi Y, Yamada K et al. Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int. 1997; 51: 182-6.
14. Hryszko T, Malyszko J, Malyszko JS, Brzosko S, Mysliwiec M. Patients on peritoneal dialysis but not on hemodialysis have elevated concentration and activity of thrombin-activatable fibrinolysis inhibitor. Thromb. Res. 2001; 104: 233-8.
15. Blankenberg S, Tiret L, Bickel C et al. AtheroGene Investigators: Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002; 106: 24-30.
16. Sepe V, Libetta C, Villa G et al. Correlation between hyperhomocysteinemia and interleukin-18 serum levels in maintenance hemodialyzed patients. Kidney Int. 2002; 62: 1900.
17. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N. Engl. J. Med. 1998; 338: 1042-50.
18. Zoccali C, Benedetto FA, Maas R. et al. Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J. Am. Soc. Nephrol. 2002; 13: 490-96.
19. Zoccali C, Bode-Boger S, Mallamaci F et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study. Lancet 2001; 358: 2113-17.
20. Böger RH, Bode-Böger SM, Szuba A. ADMA: A novel risk factor for endothelial dysfunction. Its role in hypercholesterolemia. Circulation 1998; 98: 1842-7.
21. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 2000; 342: 836-43.
22. Rupprecht HJ, Blankenberg S, Bickel C et al. Impact of viral and bacterial infectious burden on long-term prognosis in patients with coronary artery disease. Circulation 2001; 104: 25-31.
23. Duranti E, Sasdelli M. Serum B2 microgrobulin (B2M) in CAPD. Adv. Perit. Dial. 1989; 5: 195-9.
24. Whitman SC, Ravisankar P, Daugherty A. Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-gamma. Circ. Res. 2002; 90: E34-E38.
25. Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schonbeck U. Expression of interleukin (IL) -18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macropharges: Implications for atherogenesis. J. Exp. Med. 2002; 195: 245-57.
26. Anderstam B, Katzarski K, Bergstrom J. Serum levels of NG, NG-dimethyl-L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients. J. Am. Soc. Nephrol. 1997; 8: 1437-42.
27. Kielstein JT, Frolich JC, Haller H, Fliser D. ADMA (asymmetric dimethylarginine): An atherosclerotic disease mediating agent in patients with renal disease? Nephrol. Dial. Transplant. 2001; 16: 1742-5.
28. Wang AY, Woo J, Lam CW et al. Is a single time point C-reactive protein predictive of outcome in peritoneal dialysis patients?. J. Am. Soc. Nephrol. 2003; 14: 1871-9.
29. Spiegel DM, Breyer JA. Serum albumin: A predictor of long-term outcome in peritoneal dialysis patients. Am. J. Kidney Dis. 1994; 23: 283-5.
30. Chiang CK, Hsu SP, Pai MF et al. Interleukin-18 is a strong predictor of hospitalization in haemodialysis patients. Nephrol. Dial. Transplant. 2004; 19: 2810-15.
31. Moriwaki Y, Yamamoto T, Shibutani Y et al. Elevated levels of interleukin-18 and tumor necrosis factor-alpha in serum of patients with type 2 diabetes mellitus: Relationship with diabetic nephropathy. Metabolism 2003; 52: 605-8.
32. Mallat Z, Henry P, Fressonnet R. et al. Increased plasma concentrations of interleukin-18 in acute coronary syndromes. Heart 2002; 88: 467-9.